Takeda takes option on GammaDelta

Less than a year after its founding, GammaDelta Therapeutics Ltd has received an investment from Takeda Pharmaceutical Company Ltd, which sees promise in the UK company’s T cell platform as a source for new immunotherapies.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United Kingdom